(Q34886764)

5 August 2017

Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study (English)

1 reference

5 August 2017

0 references

0 references

metastatic breast cancer

1 reference

1 reference

10

Viviane Tabar

1 reference

5 August 2017

11

Patricia S Steeg

1 reference

5 August 2017

Aki Morikawa

1

1 reference

5 August 2017

David M Peereboom

2

1 reference

5 August 2017

Helen R Thorsheim

3

1 reference

5 August 2017

Ramakrishna Samala

4

1 reference

5 August 2017

Rajiv Balyan

5

1 reference

5 August 2017

Conleth G Murphy

6

1 reference

5 August 2017

Paul R Lockman

7

1 reference

5 August 2017

Ahkeem Simmons

8

1 reference

5 August 2017

Robert J Weil

9

1 reference

5 August 2017

Quentin R Smith

12

1 reference

5 August 2017

Andrew D Seidman

13

1 reference

5 August 2017

11 July 2014

1 reference

5 August 2017

1 reference

5 August 2017

17

1 reference

5 August 2017

2

1 reference

5 August 2017

289-295

1 reference

Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer

5 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4288517

Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4288517

Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4288517

"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4288517

Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4288517

A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4288517

Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4288517

The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4288517

Capecitabine therapy of central nervous system metastases from breast cancer.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4288517

The blood-brain barrier and cancer: transporters, treatment, and Trojan horses

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4288517

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4288517

CNS metastases in breast cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4288517

The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4288517

Clinical pharmacokinetics of capecitabine

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4288517

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4288517

Platinum Concentrations in Human Autopsy Tumor Samples

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4288517

Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4288517

Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier.

8 July 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOU141

Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOU141

An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOU141

A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: the mechanism for tumor-selective accumulation of 5-FU.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOU141

Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOU141

Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOU141

Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOU141

Penetration of idarubicin into malignant brain tumor tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOU141

High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery

21 January 2018

1 reference

PubMed

12 December 2020

Blood-brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and

1 reference

PubMed

12 December 2020

Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients

1 reference

PubMed

12 December 2020

1 reference

12 December 2020

Identifiers

DOI

10.1093/NEUONC/NOU141

1 reference

5 August 2017

1 reference

5 August 2017

1 reference